Print Page     Close Window     

SEC Filings

8-K
BEIGENE, LTD. filed this Form 8-K on 01/07/2019
Entire Document
 

 

Overall Response Rate (ORR) Progression Free Survival (PFS) 25 Zanubrutinib Efficacy in WM Favorable Response Depth and Durability *Of 32 efficacy evaluable patients (43%) with hemoglobin <10 g/dL at baseline, the median increased from 8.9 g/dL (range, 6.3 - 9. 8) to 13.4 g/dL (range, 7.7 - 17.0). TN: treatment naïve; RR: relapsed refractory; Data cutoff 24 July 2018. Source: Tam et al. IWWM 2018 Best Response in WM zanubrutinib Overall TN RR Evaluable for efficacy, n 73 24 49 Median Follow - up 22.5 mo 10.6 mo 23.1 mo Response Criteria Mod. 6 th IWWM (IgM and lymph node reduction) Median Prior Lines of Therapy 0 2 (1 - 8) ORR 92% 96% 90% MRR 82% 88% 80% VGPR 41% 25% 49% PR/PR - L 41% 63% 31% Median IgM Reduction (g/L) 32.7 to 8.2 (75%) Median Hb Change* (g/dl) 8.9 to 13.4

 


© 2016 BeiGene. All Rights Reserved.